Work

Epithelial–mesenchymal transition in immune escape and immunotherapy resistance of lung cancer

Year: 2026

Type: article

Abstract: Epithelial–mesenchymal transition (EMT) drives immunotherapy resistance in lung cancer through three interconnected axes: antigen/checkpoint dysregulation, chemokine remodeling, and metabolic reprogramming. We highlight partial EMT (pEMT) as a clinically prevalent hybrid state and biomarker candidate, and metabolic rewiring as an actionable immunometabolic vulnerability. EMT signatures may complement programmed death receptor ligand-1 (PD‑L1), but require treatment-by-biomarker interaction testing. Integrating these axes enables resistance-subtype stratification and precision combination therapy.

Source: npj Precision Oncology

DOI: 10.1038/s41698-026-01732-3

Authors: Jialin Jin, Die Hu, Xuelin Zong, Yuanxin Liu, Rong Hu, Shengjie Wang

Institution: The First People’s Hospital of Lianyungang

Language: English

Topic: Cancer Cells and Metastasis

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,090